Cargando…

Study protocol: Comparison of the effect of treatment with Nonsteroidal anti-inflammatory drugs added to anti-tumour necrosis factor a therapy versus anti-tumour necrosis factor a therapy alone on progression of Structural damage in the spine over two years in patients with ankyLosing spondylitis (CONSUL) – an open-label randomized controlled multicenter trial

INTRODUCTION: There is some evidence that non-steroidal anti-inflammatory drugs (NSAIDs), in particular celecoxib, might possess not only a symptomatic efficacy but also disease-modifying properties in ankylosing spondylitis (AS), retarding the progression of structural damage in the spine if taken...

Descripción completa

Detalles Bibliográficos
Autores principales: Proft, Fabian, Muche, Burkhard, Listing, Joachim, Rios-Rodriguez, Valeria, Sieper, Joachim, Poddubnyy, Denis
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5623356/
https://www.ncbi.nlm.nih.gov/pubmed/28601821
http://dx.doi.org/10.1136/bmjopen-2016-014591
_version_ 1783268066977644544
author Proft, Fabian
Muche, Burkhard
Listing, Joachim
Rios-Rodriguez, Valeria
Sieper, Joachim
Poddubnyy, Denis
author_facet Proft, Fabian
Muche, Burkhard
Listing, Joachim
Rios-Rodriguez, Valeria
Sieper, Joachim
Poddubnyy, Denis
author_sort Proft, Fabian
collection PubMed
description INTRODUCTION: There is some evidence that non-steroidal anti-inflammatory drugs (NSAIDs), in particular celecoxib, might possess not only a symptomatic efficacy but also disease-modifying properties in ankylosing spondylitis (AS), retarding the progression of structural damage in the spine if taken continuously. In contrast, this remains controversial for tumour necrosis factor alpha (TNF-α) inhibitors, despite their good clinical efficacy. The impact of a combined therapy (a TNF inhibitor plus an NSAID) on radiographic spinal progression in AS is unclear. METHODS AND ANALYSIS: The aim of this study is to evaluate the impact of treatment with an NSAID (celecoxib) when added to a TNF inhibitor (golimumab) compared with TNF inhibitor (golimumab) alone on progression of structural damage in the spine over 2 years in patients with AS. The study consists of a 6-week screening period, a 12-week period (phase I: run-in phase) of treatment with golimumab for all subjects followed by a 96-week controlled treatment period (phase II: core phase) with golimumab plus celecoxib versus golimumab alone, and a safety follow-up period of 4 weeks. At week 108, the primary study endpoint radiographic spinal progression (as assessed by the change in the modified Stoke Ankylosing Spondylitis Spine Score after 2 years) will be evaluated. ETHICS AND DISSEMINATION: The study will be performed according to the principles of good clinical practice and the German drug law. The written approval of the independent ethics committee and of the German federal authority have been obtained. On study completion, results are expected to be published in a peer-reviewed journal. TRIAL REGISTRATION NUMBER: ClinicalTrials.gov register (NCT02758782) and European Union Clinical Trials Register (EudraCT No 2016-000615-33).
format Online
Article
Text
id pubmed-5623356
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-56233562017-10-10 Study protocol: Comparison of the effect of treatment with Nonsteroidal anti-inflammatory drugs added to anti-tumour necrosis factor a therapy versus anti-tumour necrosis factor a therapy alone on progression of Structural damage in the spine over two years in patients with ankyLosing spondylitis (CONSUL) – an open-label randomized controlled multicenter trial Proft, Fabian Muche, Burkhard Listing, Joachim Rios-Rodriguez, Valeria Sieper, Joachim Poddubnyy, Denis BMJ Open Rheumatology INTRODUCTION: There is some evidence that non-steroidal anti-inflammatory drugs (NSAIDs), in particular celecoxib, might possess not only a symptomatic efficacy but also disease-modifying properties in ankylosing spondylitis (AS), retarding the progression of structural damage in the spine if taken continuously. In contrast, this remains controversial for tumour necrosis factor alpha (TNF-α) inhibitors, despite their good clinical efficacy. The impact of a combined therapy (a TNF inhibitor plus an NSAID) on radiographic spinal progression in AS is unclear. METHODS AND ANALYSIS: The aim of this study is to evaluate the impact of treatment with an NSAID (celecoxib) when added to a TNF inhibitor (golimumab) compared with TNF inhibitor (golimumab) alone on progression of structural damage in the spine over 2 years in patients with AS. The study consists of a 6-week screening period, a 12-week period (phase I: run-in phase) of treatment with golimumab for all subjects followed by a 96-week controlled treatment period (phase II: core phase) with golimumab plus celecoxib versus golimumab alone, and a safety follow-up period of 4 weeks. At week 108, the primary study endpoint radiographic spinal progression (as assessed by the change in the modified Stoke Ankylosing Spondylitis Spine Score after 2 years) will be evaluated. ETHICS AND DISSEMINATION: The study will be performed according to the principles of good clinical practice and the German drug law. The written approval of the independent ethics committee and of the German federal authority have been obtained. On study completion, results are expected to be published in a peer-reviewed journal. TRIAL REGISTRATION NUMBER: ClinicalTrials.gov register (NCT02758782) and European Union Clinical Trials Register (EudraCT No 2016-000615-33). BMJ Publishing Group 2017-06-10 /pmc/articles/PMC5623356/ /pubmed/28601821 http://dx.doi.org/10.1136/bmjopen-2016-014591 Text en © Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2017. All rights reserved. No commercial use is permitted unless otherwise expressly granted. This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
spellingShingle Rheumatology
Proft, Fabian
Muche, Burkhard
Listing, Joachim
Rios-Rodriguez, Valeria
Sieper, Joachim
Poddubnyy, Denis
Study protocol: Comparison of the effect of treatment with Nonsteroidal anti-inflammatory drugs added to anti-tumour necrosis factor a therapy versus anti-tumour necrosis factor a therapy alone on progression of Structural damage in the spine over two years in patients with ankyLosing spondylitis (CONSUL) – an open-label randomized controlled multicenter trial
title Study protocol: Comparison of the effect of treatment with Nonsteroidal anti-inflammatory drugs added to anti-tumour necrosis factor a therapy versus anti-tumour necrosis factor a therapy alone on progression of Structural damage in the spine over two years in patients with ankyLosing spondylitis (CONSUL) – an open-label randomized controlled multicenter trial
title_full Study protocol: Comparison of the effect of treatment with Nonsteroidal anti-inflammatory drugs added to anti-tumour necrosis factor a therapy versus anti-tumour necrosis factor a therapy alone on progression of Structural damage in the spine over two years in patients with ankyLosing spondylitis (CONSUL) – an open-label randomized controlled multicenter trial
title_fullStr Study protocol: Comparison of the effect of treatment with Nonsteroidal anti-inflammatory drugs added to anti-tumour necrosis factor a therapy versus anti-tumour necrosis factor a therapy alone on progression of Structural damage in the spine over two years in patients with ankyLosing spondylitis (CONSUL) – an open-label randomized controlled multicenter trial
title_full_unstemmed Study protocol: Comparison of the effect of treatment with Nonsteroidal anti-inflammatory drugs added to anti-tumour necrosis factor a therapy versus anti-tumour necrosis factor a therapy alone on progression of Structural damage in the spine over two years in patients with ankyLosing spondylitis (CONSUL) – an open-label randomized controlled multicenter trial
title_short Study protocol: Comparison of the effect of treatment with Nonsteroidal anti-inflammatory drugs added to anti-tumour necrosis factor a therapy versus anti-tumour necrosis factor a therapy alone on progression of Structural damage in the spine over two years in patients with ankyLosing spondylitis (CONSUL) – an open-label randomized controlled multicenter trial
title_sort study protocol: comparison of the effect of treatment with nonsteroidal anti-inflammatory drugs added to anti-tumour necrosis factor a therapy versus anti-tumour necrosis factor a therapy alone on progression of structural damage in the spine over two years in patients with ankylosing spondylitis (consul) – an open-label randomized controlled multicenter trial
topic Rheumatology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5623356/
https://www.ncbi.nlm.nih.gov/pubmed/28601821
http://dx.doi.org/10.1136/bmjopen-2016-014591
work_keys_str_mv AT proftfabian studyprotocolcomparisonoftheeffectoftreatmentwithnonsteroidalantiinflammatorydrugsaddedtoantitumournecrosisfactoratherapyversusantitumournecrosisfactoratherapyaloneonprogressionofstructuraldamageinthespineovertwoyearsinpatientswithankylosingspondylitiscon
AT mucheburkhard studyprotocolcomparisonoftheeffectoftreatmentwithnonsteroidalantiinflammatorydrugsaddedtoantitumournecrosisfactoratherapyversusantitumournecrosisfactoratherapyaloneonprogressionofstructuraldamageinthespineovertwoyearsinpatientswithankylosingspondylitiscon
AT listingjoachim studyprotocolcomparisonoftheeffectoftreatmentwithnonsteroidalantiinflammatorydrugsaddedtoantitumournecrosisfactoratherapyversusantitumournecrosisfactoratherapyaloneonprogressionofstructuraldamageinthespineovertwoyearsinpatientswithankylosingspondylitiscon
AT riosrodriguezvaleria studyprotocolcomparisonoftheeffectoftreatmentwithnonsteroidalantiinflammatorydrugsaddedtoantitumournecrosisfactoratherapyversusantitumournecrosisfactoratherapyaloneonprogressionofstructuraldamageinthespineovertwoyearsinpatientswithankylosingspondylitiscon
AT sieperjoachim studyprotocolcomparisonoftheeffectoftreatmentwithnonsteroidalantiinflammatorydrugsaddedtoantitumournecrosisfactoratherapyversusantitumournecrosisfactoratherapyaloneonprogressionofstructuraldamageinthespineovertwoyearsinpatientswithankylosingspondylitiscon
AT poddubnyydenis studyprotocolcomparisonoftheeffectoftreatmentwithnonsteroidalantiinflammatorydrugsaddedtoantitumournecrosisfactoratherapyversusantitumournecrosisfactoratherapyaloneonprogressionofstructuraldamageinthespineovertwoyearsinpatientswithankylosingspondylitiscon